Autoimmune polyendocrinopathy candidiasis ectodermal dystrophy and other primary immunodeficiency diseases help to resolve the nature of protective immunity against chronic mucocutaneous candidiasis

Current Opinion in Pediatrics

Volumn 25, Issue 6, 2013, Pages 715-721

  Kisand, Kai ^a   Peterson, Pärt ^a  

^a UNIVERSITY OF TARTU   (Estonia)

Author keywords

autoimmune polyendocrinopathy candidiasis ectodermal dystrophy; chronic mucocutaneous candidiasis; interleukin 22; T helper 17

Indexed keywords

BETA DEFENSIN 1; CD209 ANTIGEN; CHEMOATTRACTANT; CYSTATIN S; DECTIN 1; DECTIN 2; GALECTIN 3; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN G4; INFLAMMASOME; INTERLEUKIN 10; INTERLEUKIN 12 RECEPTO; INTERLEUKIN 17; INTERLEUKIN 17 RECEPTOR; INTERLEUKIN 17F; INTERLEUKIN 21; INTERLEUKIN 22; INTERLEUKIN 23; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE; POLYPEPTIDE ANTIBIOTIC AGENT; STAT1 PROTEIN; STAT3 PROTEIN; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADDISON DISEASE; ANTIGEN PRESENTING CELL; AUTOIMMUNE POLYENDOCRINOPATHY CANDIDIASIS ECTODERMAL DYSTROPHY; AUTOIMMUNITY; AUTOPHAGY; CANDIDA ALBICANS; CANDIDIASIS; CORYNEBACTERIUM; DEPHOSPHORYLATION; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITHELIUM CELL; FUNGUS GROWTH; GENE MUTATION; GENETIC ASSOCIATION; GENETIC CODE; GLOMERULONEPHRITIS; GRANULOPOIESIS; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; LOSS OF FUNCTION MUTATION; LYMPHOCYTE FUNCTION; MICROBIAL COMMUNITY; MICROBIOME; MUCOCUTANEOUS CANDIDIASIS; MYASTHENIA GRAVIS; NEUTROPHIL; OROPHARYNX CANDIDIASIS; PATHOGENESIS; PATHOGENICITY; PEMPHIGUS; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TH17 CELL; THROMBOCYTOPENIC PURPURA; THYMOMA; VAGINA CANDIDIASIS;

ANTIBODIES, NEUTRALIZING; ANTIFUNGAL AGENTS; AUTOIMMUNITY; CANDIDIASIS, CHRONIC MUCOCUTANEOUS; CHEMOTACTIC FACTORS; DISEASE SUSCEPTIBILITY; FEMALE; HUMANS; IMMUNITY, INNATE; INTERLEUKIN-17; INTERLEUKINS; MALE; MUTATION; POLYENDOCRINOPATHIES, AUTOIMMUNE; POLYMORPHISM, SINGLE NUCLEOTIDE; SIGNAL TRANSDUCTION; TH17 CELLS; YOUNG ADULT;

EID: 84888135330     PISSN: 10408703     EISSN: 1531698X     Source Type: Journal    
DOI: 10.1097/MOP.0000000000000028     Document Type: Review

References (66)

1. Kirkpatrick CH. Chronic mucocutaneous candidiasis. J Am Acad Dermatol.1994.31S;14-17.
2. Sillevis Smitt JH, Kuijpers TW. Cutaneous manifestations of primary immunodeficiency. Curr Opin Pediatr 2013; 25:492-497.
3. Rautemaa R, Richardson M, Pfaller M, et al. Reduction of fluconazole susceptibility of Candida albicans in APECED patients due to long-term use of ketoconazole and miconazole. Scand J Infect Dis 2008; 40:904-907.
4. Rautemaa R, Hietanen J, Niissalo S, et al. Oral and oesophageal squamous cell carcinoma: a complication or component of autoimmune polyendocrinopathy- candidiasis-ectodermal dystrophy (APECED, APS-I). Oral Oncol 2007;43:607-613.
5. Lilic D. Unravelling fungal immunity through primary immune deficiencies. Curr Opin Microbiol 2012; 15:420-426.
6. Marodi L, Cypowyj S, Toth B, et al. Molecular mechanisms of mucocutaneous immunity against Candida and Staphylococcus species. J Allergy Clin Immunol 2012; 130:1019-1027.
7. Smeekens SP, van de Veerdonk FL, Kullberg BJ, et al. Genetic susceptibility to Candida infections. EMBO Mol Med 2013; 5:805-813.
8. Cheng SC, Joosten LA, Kullberg BJ, et al. Interplay between Candida albicans and the mammalian innate host defense. Infect Immun 2012; 80:1304-1313.
9. Gauglitz GG, Callenberg H, Weindl G, et al. Host defence against Candida albicans and the role of pattern-recognition receptors. Acta Derm Venereol.2012 92;291-298.
10. Gow NA, van de Veerdonk FL, Brown AJ, et al. Candida albicans morphogenesis and host defence: discriminating invasion from colonization. Nat Rev Microbiol 2012; 10:112-122.
11. Hernandez-Santos N, Gaffen SL. Th17 cells in immunity to Candida albicans. Cell Host Microbe 2012; 11:425-435.
12. Zielinski CE, Mele F, Aschenbrenner D, et al. Pathogen-induced human TH17 cells produce IFN-gamma or IL-10 and are regulated by IL-1beta. Nature 2012; 484:514-518
13. Stockinger B, Veldhoen M. Differentiation and function of Th17 T cells. Curr Opin Immunol 2007; 19:281-286.
14. McGeachy MJ, McSorley SJ. Microbial-induced Th17: superhero or supervillain? J Immunol 2012; 189:3285-3291.
15. Yang XO, Panopoulos AD, Nurieva R, et al. STAT3 regulates cytokine-mediated generation of inflammatory helper T cells. J Biol Chem 2007; 282:9358-9363.
16. Ivanov II, McKenzie BS, Zhou L, et al. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17 T helper cells. Cell 2006; 126:1121-1133.
17. Eyerich S, Wagener J, Wenzel V, et al. IL-22 and TNF-alpha represent a key cytokine combination for epidermal integrity during infection with Candida albicans. Eur J Immunol 2011; 41:1894-1901.
18. Iwakura Y, Ishigame H, Saijo S, et al. Functional specialization of interleukin-17 family members.Immunity;2011;34:149-162
19. Rutz S, Eidenschenk C, Ouyang W. IL-22, not simply a Th17 cytokine. Immunol Rev 2013; 252:116-132.
20. Puel A, Cypowyj S, Bustamante J, et al. Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity. Science 2011;332:65-68.
21. Ma CS, Chew GY, Simpson N, et al. Deficiency of Th17 cells in hyper IgE syndrome due to mutations in STAT3. J Exp Med 2008; 205:1551-1557.
22. Milner JD, Brenchley JM, Laurence A, et al. Impaired T(H)17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome. Nature 2008;452:773-776.
23. Minegishi Y, Saito M, Tsuchiya S, et al. Dominant-negative mutations in the DNA-binding domain of STAT3 cause hyper-IgE syndrome. Nature;2007;448:1058- 1062.
24. Minegishi Y, Saito M. Molecular mechanisms of the immunological abnormalities in hyper-IgE syndrome. Ann N Y Acad Sci 2011; 1246:34-40.
25. de Beaucoudrey L, Puel A, Filipe-Santos O, et al. Mutations in STAT3 and IL12RB1 impair the development of human IL-17-producing T cells. J Exp Med. 2008;205:1543-1550.
26. de Beaucoudrey L, Samarina A, Bustamante J, et al. Revisiting human IL-12Rbeta1 deficiency: a survey of 141 patients from 30 countries. Medicine (Baltimore) 2010; 89:381-402.
27. Liu L, Okada S, Kong XF, et al. Gain-of-function human STAT1 mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis. J Exp Med 2011; 208:1635-1648.
28. van de Veerdonk FL, Plantinga TS, Hoischen A, et al. STAT1 mutations in autosomal dominant chronic mucocutaneous candidiasis. N Engl J Med, 2011;365:54-61.
29. Boisson-Dupuis S, Kong XF, Okada S, et al. Inborn errors of human STAT1: allelic heterogeneity governs the diversity of immunological and infectious phenotypes. Curr Opin Immunol 2012; 24:364-378.
30. Smeekens SP, Plantinga TS, van de Veerdonk FL, et al. STAT1 hyperphosphorylation and defective IL12R/IL23R signaling underlie defective immunity in autosomal dominant chronic mucocutaneous candidiasis. PLoS One 2011;6:e29248.
31. Axtell RC, Raman C. Janus-like effects of type I interferon in autoimmune diseases. Immunol Rev 2012; 248:23-35.
32. Mitani Y, Takaoka A, Kim SH, et al. Cross talk of the interferon-alpha/beta signalling complex with gp130 for effective interleukin-6 signalling. Genes Cells 2001; 6:631-640.
33. Del Fresno C, Soulat D, Roth S, et al. Interferon-beta production via dectin-1-Syk-IRF5 signaling in dendritic cells is crucial for immunity to C. albicans. Immunity 2013; 38:1176-1186.
34. Smeekens SP, Ng A, Kumar V, et al. Functional genomics identifies type I interferon pathway as central for host defense against Candida albicans. Nat Commun 2013; 4:1342.
35. de Veer MJ, Holko M, Frevel M, et al. Functional classification of interferonstimulated genes identified using microarrays. J Leukoc Biol 2001; 69:912-920.
36. Nagamine K, Peterson P, Scott HS, et al. Positional cloning of the APECED gene. Nat Genet 1997; 17:393-398.
37. Husebye ES, Perheentupa J, Rautemaa R, et al. Clinical manifestations and management of patients with autoimmune polyendocrine syndrome type I. J Intern Med 2009; 265:514-529.
38. Perheentupa J. Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. J Clin Endocrinol Metab 2006; 91:2843-2850.
39. Peterson P, Org T, Rebane A. Transcriptional regulation by AIRE: molecular mechanisms of central tolerance. Nat Rev Immunol 2008; 8:948-957.
40. Derbinski J, Gabler J, Brors B, et al. Promiscuous gene expression in thymic epithelial cells is regulated at multiple levels. J Exp Med 2005; 202:33-45.
41. Kisand K, Boe Wolff AS, Podkrajsek KT, et al. Chronic mucocutaneous candidiasis in APECED or thymoma patients correlates with autoimmunity to Th17-associated cytokines. J Exp Med 2010; 207:299-308.
42. Puel A, Doffinger R, Natividad A, et al. Autoantibodies against IL-17A, IL-17F, and IL-22 in patients with chronic mucocutaneous candidiasis and autoimmune polyendocrine syndrome type I. J Exp Med 2010; 207:291-297.
43. Meager A, Visvalingam K, Peterson P, et al. Anti-interferon autoantibodies in autoimmune polyendocrinopathy syndrome type 1. PLoS Med 2006;3:e289.
44. Meager A, Vincent A, Newsom-Davis J, et al. Spontaneous neutralising antibodies to interferon-alpha and interleukin-12 in thymoma-associated autoimmune disease. Lancet 1997; 350:1596-1597.
45. Meloni A, Furcas M, Cetani F, et al. Autoantibodies against type I interferons as an additional diagnostic criterion for autoimmune polyendocrine syndrome type I. J Clin Endocrinol Metab 2008; 93:4389-4397.
46. Kisand K, Peterson P. Autoimmune polyendocrinopathy candidiasis ectodermal dystrophy: known and novel aspects of the syndrome. Ann N Y Acad Sci 2012; 1246:77-91.
47. Kisand K, Link M, Wolff AS, et al. Interferon autoantibodies associated with AIRE deficiency decrease the expression of IFN-stimulated genes. Blood 2008; 112:2657-2666.
48. Ahlgren KM, Moretti S, Lundgren BA, et al. Increased IL-17A secretion in response to Candida albicans in autoimmune polyendocrine syndrome type 1 and its animal model. Eur J Immunol 2011; 41:235-245.
49. Ng WF, von Delwig A, Carmichael AJ, et al. Impaired T(H)17 responses in patients with chronic mucocutaneous candidiasis with and without autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. J Allergy Clin Immunol 2010; 126:1006-1015; e1004.
50. Zelante T, Iannitti RG, De Luca A, et al. Sensing of mammalian IL-17A regulates fungal adaptation and virulence. Nat Commun 2012; 3:683.
51. De Luca A, Carvalho A, Cunha C, et al. IL-22 and IDO1 affect immunity and tolerance to murine and human vaginal candidiasis. PLoS Pathog 2013;9:e1003486
52. Wright JF, Guo Y, Quazi A, et al. Identification of an interleukin 17F/17A heterodimer in activated human CD4 T cells. J Biol Chem 2007; 282:13447-13455.
53. Oftedal BE, Kampe O, Meager A, et al. Measuring autoantibodies against IL-17F and IL-22 in autoimmune polyendocrine syndrome type I by radioligand binding assay using fusion proteins. Scand J Immunol 2011; 74:327-333.
54. Lindh E, Brannstrom J, Jones P, et al. Autoimmunity and cystatin SA1 deficiency behind chronic mucocutaneous candidiasis in autoimmune polyendocrine syndrome type 1. J Autoimmun 2013; 42:1-6.
55. Kisand K, Lilic D, Casanova JL, et al. Mucocutaneous candidiasis and autoimmunity against cytokines in APECED and thymoma patients: clinical and pathogenetic implications. Eur J Immunol 2011; 41:1517-1527.
56. Karner J, Meager A, Laan M, et al. Anticytokine autoantibodies suggest pathogenetic links with autoimmune regulator deficiency in humans and mice. Clin Exp Immunol 2013; 171:263-272.
57. Schroeder HW Jr, Cavacini L. Structure and function of immunoglobulins. J Allergy Clin Immunol 2010; 125:S41-S52.
58. Plomp JJ, Huijbers MG, van der Maarel SM, et al. Pathogenic IgG4 subclass autoantibodies in MuSK myasthenia gravis. Ann N Y Acad Sci 2012; 1275:114-122.
59. Meager A, Peterson P, Willcox N. Hypothetical review: thymic aberrations and type-I interferons; attempts to deduce autoimmunizing mechanisms from unexpected clues in monogenic and paraneoplastic syndromes. Clin Exp Immunol 2008; 154:141-151.
60. Strobel P, Murumagi A, Klein R, et al. Deficiency of the autoimmune regulator AIRE in thymomas is insufficient to elicit autoimmune polyendocrinopathy syndrome type 1 (APS-1). J Pathol 2007; 211:563-571.
61. Marx A, Willcox N, Leite MI, et al. Thymoma and paraneoplastic myasthenia gravis. Autoimmunity 2010; 43:413-427.
62. Gladiator A, Wangler N, Trautwein-Weidner K, et al. Cutting edge: IL-17-secreting innate lymphoid cells are essential for host defense against fungal infection. J Immunol 2013; 190:521-525.
63. Spits H, Artis D, Colonna M, et al. Innate lymphoid cells: a proposal for uniform nomenclature. Nat Rev Immunol 2013; 13:145-149.
64. Conti HR, Baker O, Freeman AF, et al. New mechanism of oral immunity to mucosal candidiasis in hyper-IgE syndrome. Mucosal Immunol 2011; 4:448-455.
65. Ivanov II, Atarashi K, Manel N, et al. Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell 2009; 139:485-498.
66. Smeekens SP, Huttenhower C, Riza A, et al. Skin microbiome imbalance in patients with STAT1/STAT3 defects impairs innate host defense responses. J Innate Immun 2013.